Read by QxMD icon Read


Francesco Sanguedolce, Giuseppe Petralia, Heminder Sokhi, Elena Tagliabue, Nicola Anyamene, Giles Hellawell, Anwar R Padhani
INTRODUCTION: Increasing evidence has supported the use of multiparametric magnetic resonance imaging (mpMRI) for the detection of prostate cancer. However, its role in selecting patients clinically suitable for active surveillance (AS) is still in development. We aimed to find relevant mpMRI features that might be helpful for refinement of the selection of low-risk prostate cancer patients for AS. We also evaluated the interobserver variability in reporting prostate mpMRI features. PATIENTS AND METHODS: From 2008 to 2012, 135 patients were selected for AS using Epstein criteria...
November 21, 2017: Clinical Genitourinary Cancer
Anna Barnes, Roberto Alonzi, Matthew Blackledge, Geoff Charles-Edwards, David J Collins, Gary Cook, Glynn Coutts, Vicky Goh, Martin Graves, Charles Kelly, Dow-Mu Koh, Hazel McCallum, Marc E Miquel, James O'Connor, Anwar Padhani, Rachel Pearson, Andrew Priest, Andrea Rockall, James Stirling, Stuart Taylor, Nina Tunariu, Jan van der Meulen, Darren Walls, Jessica Winfield, Shonit Punwani
OBJECTIVE: Application of whole body diffusion-weighted MRI (WB-DWI) for oncology are rapidly increasing within both research and routine clinical domains. However, WB-DWI as a quantitative imaging biomarker (QIB) has significantly slower adoption. To date, challenges relating to accuracy and reproducibility, essential criteria for a good QIB, have limited widespread clinical translation. In recognition, a UK workgroup was established in 2016 to provide technical consensus guidelines (to maximise accuracy and reproducibility of WB-MRI QIBs) and accelerate the clinical translation of quantitative WB-DWI applications for oncology...
January 2018: British Journal of Radiology
Silke Gillessen, Gerhardt Attard, Tomasz M Beer, Himisha Beltran, Alberto Bossi, Rob Bristow, Brett Carver, Daniel Castellano, Byung Ha Chung, Noel Clarke, Gedske Daugaard, Ian D Davis, Johann de Bono, Rodolfo Borges Dos Reis, Charles G Drake, Ros Eeles, Eleni Efstathiou, Christopher P Evans, Stefano Fanti, Felix Feng, Karim Fizazi, Mark Frydenberg, Martin Gleave, Susan Halabi, Axel Heidenreich, Celestia S Higano, Nicolas James, Philip Kantoff, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B Khauli, Gero Kramer, Chris Logothetis, Fernando Maluf, Alicia K Morgans, Michael J Morris, Nicolas Mottet, Vedang Murthy, William Oh, Piet Ost, Anwar R Padhani, Chris Parker, Colin C Pritchard, Mack Roach, Mark A Rubin, Charles Ryan, Fred Saad, Oliver Sartor, Howard Scher, Avishay Sella, Neal Shore, Matthew Smith, Howard Soule, Cora N Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R Sydes, Ian Tannock, Bertrand Tombal, Riccardo Valdagni, Thomas Wiegel, Aurelius Omlin
BACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics. OBJECTIVE: To present the report of APCCC 2017. DESIGN, SETTING, AND PARTICIPANTS: Ten important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; "oligometastatic" prostate cancer; castration-naïve and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs...
February 2018: European Urology
Stuart A Taylor, Sue Mallett, Anne Miles, Sandy Beare, Gauraang Bhatnagar, John Bridgewater, Rob Glynne-Jones, Vicky Goh, Ashley M Groves, Sam M Janes, Dow Mu Koh, Steve Morris, Alison Morton, Neal Navani, Alf Oliver, Anwar R Padhani, Shonit Punwani, Andrea G Rockall, Steve Halligan
BACKGROUND AND AIMS: Rapid and accurate cancer staging following diagnosis underpins patient management, in particular the identification of distant metastatic disease. Current staging guidelines recommend sequential deployment of various imaging platforms such as computerised tomography (CT) and positron emission tomography (PET) which can be time and resource intensive and onerous for patients. Recent studies demonstrate that whole body magnetic resonance Imaging (WB-MRI) may stage cancer efficiently in a single visit, with potentially greater accuracy than current staging investigations...
May 2, 2017: BMC Cancer
Michael Kosmin, Andreas Makris, Priya V Joshi, Mei-Lin Ah-See, David Woolf, Anwar R Padhani
AIM: Accurate evaluation of distribution of disease and response to systemic anti-cancer therapy (SACT) is important in the optimal management of metastatic breast cancer. Whole-body magnetic resonance imaging (WB-MRI) has increased accuracy over computerised tomography of the chest, abdomen and pelvis (CT-CAP) for detecting liver and bone disease, but its effect on patient management is largely unexplored. This study investigates the effects of using WB-MRI alongside CT-CAP on SACT decisions in standard clinical practice for patients with metastatic breast cancer...
May 2017: European Journal of Cancer
Michael Kosmin, Andreas Makris, Noorulhuda Jawad, David Woolf, David Miles, Anwar R Padhani
BACKGROUND: An association between trastuzumab-emtansine (T-DM1) and splenic enlargement is reported in preclinical data, and has been noted anecdotally in patients receiving T-DM1 at our institution. Use of whole-body MRI examinations (WB-MRI) allows for detailed bone marrow assessment and semi-automated splenic volume calculations. OBJECTIVE: To retrospectively evaluate changes in splenic volume versus evidence of bone marrow hyperplasia and/or changes in portal venous pressure in patients receiving T-DM1 for metastatic breast cancer...
April 2017: Targeted Oncology
Gary J R Cook, Gurdip Azad, Anwar R Padhani
The bone scan continues to be recommended for both the staging and therapy response assessment of skeletal metastases from prostate cancer. However, it is widely recognised that bone scans have limited sensitivity for disease detection and is both insensitive and non-specific for determining treatment response, at an early enough time point to be clinically useful. We, therefore, review the evolving roles of nuclear medicine and radiology for this application. We have reviewed the published literature reporting recent developments in imaging bone metastases in prostate cancer, and provide a balanced synopsis of the state of the art...
2016: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
James P B O'Connor, Eric O Aboagye, Judith E Adams, Hugo J W L Aerts, Sally F Barrington, Ambros J Beer, Ronald Boellaard, Sarah E Bohndiek, Michael Brady, Gina Brown, David L Buckley, Thomas L Chenevert, Laurence P Clarke, Sandra Collette, Gary J Cook, Nandita M deSouza, John C Dickson, Caroline Dive, Jeffrey L Evelhoch, Corinne Faivre-Finn, Ferdia A Gallagher, Fiona J Gilbert, Robert J Gillies, Vicky Goh, John R Griffiths, Ashley M Groves, Steve Halligan, Adrian L Harris, David J Hawkes, Otto S Hoekstra, Erich P Huang, Brian F Hutton, Edward F Jackson, Gordon C Jayson, Andrew Jones, Dow-Mu Koh, Denis Lacombe, Philippe Lambin, Nathalie Lassau, Martin O Leach, Ting-Yim Lee, Edward L Leen, Jason S Lewis, Yan Liu, Mark F Lythgoe, Prakash Manoharan, Ross J Maxwell, Kenneth A Miles, Bruno Morgan, Steve Morris, Tony Ng, Anwar R Padhani, Geoff J M Parker, Mike Partridge, Arvind P Pathak, Andrew C Peet, Shonit Punwani, Andrew R Reynolds, Simon P Robinson, Lalitha K Shankar, Ricky A Sharma, Dmitry Soloviev, Sigrid Stroobants, Daniel C Sullivan, Stuart A Taylor, Paul S Tofts, Gillian M Tozer, Marcel van Herk, Simon Walker-Samuel, James Wason, Kaye J Williams, Paul Workman, Thomas E Yankeelov, Kevin M Brindle, Lisa M McShane, Alan Jackson, John C Waterton
Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification...
March 2017: Nature Reviews. Clinical Oncology
Shaveta Mehta, Nick P Hughes, Sonia Li, Adrian Jubb, Rosie Adams, Simon Lord, Lefteris Koumakis, Ruud van Stiphout, Anwar Padhani, Andreas Makris, Francesca M Buffa, Adrian L Harris
Anti-VEGF antibody bevacizumab has prolonged progression-free survival in several cancer types, however acquired resistance is common. Adaption has been observed pre-clinically, but no human study has shown timing and genes involved, enabling formulation of new clinical paradigms. In a window-of-opportunity study in 35 ductal breast cancer patients for 2weeks prior to neoadjuvant chemotherapy, we monitored bevacizumab response by Dynamic Contrast-Enhanced Magnetic Resonance [DCE-MRI], transcriptomic and pathology...
August 2016: EBioMedicine
Caroline M Moore, Francesco Giganti, Peter Albertsen, Clare Allen, Chris Bangma, Alberto Briganti, Peter Carroll, Masoom Haider, Veeru Kasivisvanathan, Alex Kirkham, Laurence Klotz, Adil Ouzzane, Anwar R Padhani, Valeria Panebianco, Peter Pinto, Philippe Puech, Antti Rannikko, Raphaele Renard-Penna, Karim Touijer, Baris Turkbey, Heinrik van Poppel, Riccardo Valdagni, Jochen Walz, Ivo Schoots
BACKGROUND: Published data on prostate magnetic resonance imaging (MRI) during follow-up of men on active surveillance are lacking. Current guidelines for prostate MRI reporting concentrate on prostate cancer (PCa) detection and staging. A standardised approach to prostate MRI reporting for active surveillance will facilitate the robust collection of evidence in this newly developing area. OBJECTIVE: To develop preliminary recommendations for reporting of individual MRI studies in men on active surveillance and for researchers reporting the outcomes of cohorts of men having MRI on active surveillance...
April 2017: European Urology
Anwar R Padhani, Frederic E Lecouvet, Nina Tunariu, Dow-Mu Koh, Frederik De Keyzer, David J Collins, Evis Sala, Heinz Peter Schlemmer, Giuseppe Petralia, H Alberto Vargas, Stefano Fanti, H Bertrand Tombal, Johann de Bono
CONTEXT: Comparative reviews of whole-body magnetic resonance imaging (WB-MRI) and positron emission tomography/computed tomography (CT; with different radiotracers) have shown that metastasis detection in advanced cancers is more accurate than with currently used CT and bone scans. However, the ability of WB-MRI and positron emission tomography/CT to assess therapeutic benefits has not been comprehensively evaluated. There is also considerable variability in the availability and quality of WB-MRI, which is an impediment to clinical development...
January 2017: European Urology
Ahmed Larbi, Benjamin Dallaudière, Vasiliki Pasoglou, Anwar Padhani, Nicolas Michoux, Bruno C Vande Berg, Bertrand Tombal, Frédéric E Lecouvet
OBJECTIVES: To determine the proportion of prostate cancer (PCa) patients with oligometastatic disease (≤3 synchronous lesions) using whole body magnetic resonance imaging with diffusion-weighted imaging (WB-MRI/DWI). To determine the proportion of patients with nodal disease confined within currently accepted target areas for extended lymph node dissection (eLND) and pelvic external beam radiation therapy (EBRT). SUBJECTS AND METHODS: Two radiologists reviewed WB-MRI/DWI studies in 96 consecutive newly diagnosed metastatic PCa patients; 46 patients with newly diagnosed castration naive PCa (mHNPC) and 50 patients with first appearance of metastasis during monitoring for non-metastatic castration resistant PCa (M0 to mCRPC)...
August 2016: Prostate
David K Woolf, N Jane Taylor, Andreas Makris, Nina Tunariu, David J Collins, Sonia P Li, Mei-Lin Ah-See, Mark Beresford, Anwar R Padhani
OBJECTIVE: To evaluate the performance of six models of population arterial input function (AIF) in the setting of primary breast cancer and neoadjuvant chemotherapy (NAC). The ability to fit patient dynamic contrast-enhanced MRI (DCE-MRI) data, provide physiological plausible data and detect pathological response was assessed. METHODS: Quantitative DCE-MRI parameters were calculated for 27 patients at baseline and after 2 cycles of NAC for 6 AIFs. Pathological complete response detection was compared with change in these parameters from a reproduction cohort of 12 patients using the Bland-Altman approach and receiver-operating characteristic analysis...
July 2016: British Journal of Radiology
S Gillessen, A Omlin, G Attard, J S de Bono, E Efstathiou, K Fizazi, S Halabi, P S Nelson, O Sartor, M R Smith, H R Soule, H Akaza, T M Beer, H Beltran, A M Chinnaiyan, G Daugaard, I D Davis, M De Santis, C G Drake, R A Eeles, S Fanti, M E Gleave, A Heidenreich, M Hussain, N D James, F E Lecouvet, C J Logothetis, K Mastris, S Nilsson, W K Oh, D Olmos, A R Padhani, C Parker, M A Rubin, J A Schalken, H I Scher, A Sella, N D Shore, E J Small, C N Sternberg, H Suzuki, C J Sweeney, I F Tannock, B Tombal
No abstract text is available yet for this article.
May 2, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Roberto García-Figueiras, Sandra Baleato-González, Anwar R Padhani, Ana Marhuenda, Antonio Luna, Lidia Alcalá, Ana Carballo-Castro, Ana Álvarez-Castro
UNLABELLED: Imaging techniques play a key role in the management of patients with colorectal cancer. The introduction of new advanced anatomical, functional, and molecular imaging techniques may improve the assessment of diagnosis, prognosis, planning therapy, and assessment of response to treatment of these patients. Functional and molecular imaging techniques in clinical practice may allow the assessment of tumour-specific characteristics and tumour heterogeneity. This paper will review recent developments in imaging technologies and the evolving roles for these techniques in colorectal cancer...
June 2016: Insights Into Imaging
Matthew D Blackledge, Nina Tunariu, Matthew R Orton, Anwar R Padhani, David J Collins, Martin O Leach, Dow-Mu Koh
Quantitative whole-body diffusion-weighted MRI (WB-DWI) is now possible using semi-automatic segmentation techniques. The method enables whole-body estimates of global Apparent Diffusion Coefficient (gADC) and total Diffusion Volume (tDV), both of which have demonstrated considerable utility for assessing treatment response in patients with bone metastases from primary prostate and breast cancers. Here we investigate the agreement (inter-observer repeatability) between two radiologists in their definition of Volumes Of Interest (VOIs) and subsequent assessment of tDV and gADC on an exploratory patient cohort of nine...
2016: PloS One
Bachir Taouli, Ambros J Beer, Thomas Chenevert, David Collins, Constance Lehman, Celso Matos, Anwar R Padhani, Andrew B Rosenkrantz, Amita Shukla-Dave, Eric Sigmund, Lawrence Tanenbaum, Harriet Thoeny, Isabelle Thomassin-Naggara, Sebastiano Barbieri, Idoia Corcuera-Solano, Matthew Orton, Savannah C Partridge, Dow-Mu Koh
The significant advances in magnetic resonance imaging (MRI) hardware and software, sequence design, and postprocessing methods have made diffusion-weighted imaging (DWI) an important part of body MRI protocols and have fueled extensive research on quantitative diffusion outside the brain, particularly in the oncologic setting. In this review, we summarize the most up-to-date information on DWI acquisition and clinical applications outside the brain, as discussed in an ISMRM-sponsored symposium held in April 2015...
September 2016: Journal of Magnetic Resonance Imaging: JMRI
Roberto García-Figueiras, Sandra Baleato-González, Anwar R Padhani, Laura Oleaga, Joan C Vilanova, Antonio Luna, Juan Carlos Cobas Gómez
Abnormal metabolism is a key tumor hallmark. Proton magnetic resonance spectroscopy (1H-MRS) allows measurement of metabolite concentration that can be utilized to characterize tumor metabolic changes. 1H-MRS measurements of specific metabolites have been implemented in the clinic. This article performs a systematic review of image acquisition and interpretation of 1H-MRS for cancer evaluation, evaluates its strengths and limitations, and correlates metabolite peaks at 1H-MRS with diagnostic and prognostic parameters of cancer in different tumor types...
January 2016: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
Roberto García-Figueiras, Anwar R Padhani, Sandra Baleato-González
Cancer therapy is mainly based on different combinations of surgery, radiotherapy, and chemotherapy. Additionally, targeted therapies (designed to disrupt specific tumor hallmarks, such as angiogenesis, metabolism, proliferation, invasiveness, and immune evasion), hormonotherapy, immunotherapy, and interventional techniques have emerged as alternative oncologic treatments. Conventional imaging techniques and current response criteria do not always provide the necessary information regarding therapy success particularly to targeted therapies...
February 2016: Magnetic Resonance Imaging Clinics of North America
Jelle O Barentsz, Jeffrey C Weinreb, Sadhna Verma, Harriet C Thoeny, Clare M Tempany, Faina Shtern, Anwar R Padhani, Daniel Margolis, Katarzyna J Macura, Masoom A Haider, Francois Cornud, Peter L Choyke
No abstract text is available yet for this article.
January 2016: European Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"